Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CAR-T cell dosing approaches in treating acute lymphoblastic leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.12.18
Views: 631

Prof Bijal Shah - H. Lee Moffitt Cancer Centre & Research Institute, Tampa, USA

Prof Bijal Shah speaks to ecancer at ASH 2018 about the updated results of the ZUMA-3 phase I trial, which explores different CAR-T cell dosing approaches in adults with acute lymphoblastic leukaemia.

He explains that with the modified dosing approach used they found improvements in tolerability.

Prof Shah reports that the study found the lowest rate of neurotoxicity of the adult ALL trials.


ASH 2018

Related videos


no rating
Cancer care in Latin America

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation